PHASE 3 TRIAL OF SHR8058 EYE DROPS (PERFLUOROHEXYLOCTANE) COND...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
HEIDELBERG, Germany, and CAMBRIDGE, Mass., Dec. 16, 2021 /PRNewswire-AsiaNet/-- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol(R) water-free technology, today provided a development update on the phase 3 trial of SHR8058 eye drops (perfluorohexyloctane)...
Authors: LATEST ASIANET NEWS RELEASES